About
AAV-based gene therapies
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyNJ, NY, PA
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
180
By Phase
PHASE1: 1PHASE1/PHASE2: 4
By Status
RECRUITING: 4ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06565195Lead Sponsor
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
PHASE1Recruiting
108 participants
Started: Aug 27, 2024 · Completed: May 5, 2029
NCT05487599Lead Sponsor
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
PHASE1/PHASE2Recruiting
15 participants
Started: Dec 20, 2022 · Completed: Oct 2, 2030
NCT04411654Lead Sponsor
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
PHASE1/PHASE2Active, not recruiting
7 participants
Started: Jun 29, 2021 · Completed: May 31, 2028
NCT04408625Lead Sponsor
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
PHASE1/PHASE2Recruiting
30 participants
Started: Nov 9, 2020 · Completed: Apr 30, 2030
NCT04127578Lead Sponsor
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
PHASE1/PHASE2Recruiting
20 participants
Started: Jan 3, 2020 · Completed: Dec 31, 2030
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...